317 related articles for article (PubMed ID: 27267119)
1. In vitro impact of pegvisomant on growth hormone-secreting pituitary adenoma cells.
Cuny T; Zeiller C; Bidlingmaier M; Défilles C; Roche C; Blanchard MP; Theodoropoulou M; Graillon T; Pertuit M; Figarella-Branger D; Enjalbert A; Brue T; Barlier A
Endocr Relat Cancer; 2016 Jul; 23(7):509-19. PubMed ID: 27267119
[TBL] [Abstract][Full Text] [Related]
2. In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas.
Gatto F; Feelders RA; Franck SE; van Koetsveld PM; Dogan F; Kros JM; Neggers SJCMM; van der Lely AJ; Lamberts SWJ; Ferone D; Hofland LJ
J Clin Endocrinol Metab; 2017 Jun; 102(6):2009-2018. PubMed ID: 28323931
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH, and PRL secretion.
Zatelli MC; Piccin D; Tagliati F; Ambrosio MR; Margutti A; Padovani R; Scanarini M; Culler MD; degli Uberti EC
J Clin Endocrinol Metab; 2003 Jun; 88(6):2797-802. PubMed ID: 12788890
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.
Franck SE; Gatto F; van der Lely AJ; Janssen JAMJL; Dallenga AHG; Nagtegaal AP; Hofland LJ; Neggers SJCMM
Neuroendocrinology; 2017; 105(1):44-53. PubMed ID: 27455094
[TBL] [Abstract][Full Text] [Related]
5. Cortistatin inhibits growth hormone release from human fetal and adenoma pituitary cells and prolactin secretion from cultured prolactinomas.
Rubinfeld H; Hadani M; Barkai G; Taylor JE; Culler MD; Shimon I
J Clin Endocrinol Metab; 2006 Jun; 91(6):2257-63. PubMed ID: 16595604
[TBL] [Abstract][Full Text] [Related]
6. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro.
Hofland LJ; van der Hoek J; van Koetsveld PM; de Herder WW; Waaijers M; Sprij-Mooij D; Bruns C; Weckbecker G; Feelders R; van der Lely AJ; Beckers A; Lamberts SW
J Clin Endocrinol Metab; 2004 Apr; 89(4):1577-85. PubMed ID: 15070915
[TBL] [Abstract][Full Text] [Related]
7. Basic fibroblastic growth factor stimulates prolactin secretion from human anterior pituitary adenomas without affecting adenoma cell proliferation.
Atkin SL; Landolt AM; Jeffreys RV; Diver M; Radcliffe J; White MC
J Clin Endocrinol Metab; 1993 Sep; 77(3):831-7. PubMed ID: 8370706
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis and treatment of pituitary adenomas.
Chanson P; Salenave S
Minerva Endocrinol; 2004 Dec; 29(4):241-75. PubMed ID: 15765032
[TBL] [Abstract][Full Text] [Related]
9. Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro.
Zatelli MC; Piccin D; Tagliati F; Bottoni A; Ambrosio MR; Margutti A; Scanarini M; Bondanelli M; Culler MD; degli Uberti EC
J Mol Endocrinol; 2005 Oct; 35(2):333-41. PubMed ID: 16216913
[TBL] [Abstract][Full Text] [Related]
10. Direct effects of catecholamines, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture.
Ishibashi M; Yamaji T
J Clin Invest; 1984 Jan; 73(1):66-78. PubMed ID: 6140273
[TBL] [Abstract][Full Text] [Related]
11. STAT3 upregulation in pituitary somatotroph adenomas induces growth hormone hypersecretion.
Zhou C; Jiao Y; Wang R; Ren SG; Wawrowsky K; Melmed S
J Clin Invest; 2015 Apr; 125(4):1692-702. PubMed ID: 25774503
[TBL] [Abstract][Full Text] [Related]
12. Effect of vasoactive intestinal polypeptide (VIP) on growth hormone (GH) and prolactin (PRL) release and cell morphology in human pituitary adenoma cell cultures.
Fazekas I; Bácsy E; Varga I; Slowik F; Bálint K; Pásztor E; Czirják S; Gláz E
Folia Histochem Cytobiol; 2000; 38(3):119-27. PubMed ID: 10970071
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of transcription factor pit-1 to target tumoral somatolactotroph cells.
Roche C; Rasolonjanahary R; Thirion S; Goddard I; Fusco A; Figarella-Branger D; Dufour H; Brue T; Franc JL; Enjalbert A; Barlier A
Hum Gene Ther; 2012 Jan; 23(1):104-14. PubMed ID: 21942649
[TBL] [Abstract][Full Text] [Related]
14. Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter study.
Filopanti M; Olgiati L; Mantovani G; Corbetta S; Arosio M; Gasco V; De Marinis L; Martini C; Bogazzi F; Cannavò S; Colao A; Ferone D; Arnaldi G; Pigliaru F; Peri A; Angeletti G; Jaffrain-Rea ML; Lania AG; Spada A
J Clin Endocrinol Metab; 2012 Feb; 97(2):E165-72. PubMed ID: 22162472
[TBL] [Abstract][Full Text] [Related]
15. Growth hormone receptor expression and function in pituitary adenomas.
Clausen LR; Kristiansen MT; Rasmussen LM; Billestrup N; Blaabjerg O; Ledet T; Jørgensen JO
Clin Endocrinol (Oxf); 2004 May; 60(5):576-83. PubMed ID: 15104560
[TBL] [Abstract][Full Text] [Related]
16. Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes.
Jaquet P; Saveanu A; Gunz G; Fina F; Zamora AJ; Grino M; Culler MD; Moreau JP; Enjalbert A; Ouafik LH
J Clin Endocrinol Metab; 2000 Feb; 85(2):781-92. PubMed ID: 10690891
[TBL] [Abstract][Full Text] [Related]
17. Different responses of growth hormone secretion to guanfacine, bromocriptine, and thyrotropin-releasing hormone in acromegalic patients with pure growth hormone (GH)-containing and mixed GH/prolactin-containing pituitary adenomas.
Lamberts SW; Klijn JG; van Vroonhoven CC; Stefanko SZ
J Clin Endocrinol Metab; 1985 Jun; 60(6):1148-53. PubMed ID: 3923021
[TBL] [Abstract][Full Text] [Related]
18. Effects of hypophysiotropic factors on growth hormone and prolactin secretion from somatotroph adenomas in culture.
Ishibashi M; Yamaji T
J Clin Endocrinol Metab; 1985 May; 60(5):985-93. PubMed ID: 2858494
[TBL] [Abstract][Full Text] [Related]
19. Prolactin (PRL)-releasing peptide stimulates PRL secretion from human fetal pituitary cultures and growth hormone release from cultured pituitary adenomas.
Rubinek T; Hadani M; Barkai G; Melmed S; Shimon I
J Clin Endocrinol Metab; 2001 Jun; 86(6):2826-30. PubMed ID: 11397894
[TBL] [Abstract][Full Text] [Related]
20. Serum prolactin and growth hormone response to thyrotropin-releasing hormone in patients with pituitary adenomas.
Chang CC; Chen FW; Hsieh HC
Taiwan Yi Xue Hui Za Zhi; 1989 May; 88(5):443-9. PubMed ID: 2507734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
